Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Lab and Cosmetic PCLBKK:BLC -0.52%65 Debt-to-Equity is 0.23 as of Jun. 2026, which is 53% above its 10-year median of 0.15. GuruFocus rates BKK:BLC with a GF Score™ of 65/100 and a GF Value™ of ฿4.75 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,753 Consumer Packaged Goods companies, Bangkok Lab and Cosmetic PCL ranks better than 65.72% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bangkok Lab and Cosmetic PCL's Debt-to-Equity or its related term are showing as below:
BKK:BLC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.15 Max: 2.88
Current: 0.23
During the past 5 years, the highest Debt-to-Equity Ratio of Bangkok Lab and Cosmetic PCL was 2.88. The lowest was 0.07. And the median was 0.15.
BKK:BLC's Debt-to-Equity is ranked better than 65.72% of 1753
companies
in the Consumer Packaged Goods industry
Industry Median: 0.42
vs BKK:BLC: 0.23
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bangkok Lab and Cosmetic PCL Debt-to-Equity Related Terms
Bangkok Lab and Cosmetic PCL Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BLC vs PG, CL, KVUE: Debt-to-Equity Comparison
For the Household & Personal Products subindustry, Bangkok Lab and Cosmetic PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Lab and Cosmetic PCL Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bangkok Lab and Cosmetic PCL's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bangkok Lab and Cosmetic PCL's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Lab and Cosmetic PCL (BKK:BLC) has a Debt-to-Equity of 0.23 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bangkok Lab and Cosmetic PCL and its competitors. This is 53% above median its historical median of 0.15. Over the past decade, Bangkok Lab and Cosmetic PCL's Debt-to-Equity has ranged from 0.07 to 2.88. According to the industry distribution chart, Bangkok Lab and Cosmetic PCL ranks #601 out of 1753 companies in the Consumer Packaged Goods industry, placing it in the top 34.3%.
Is Bangkok Lab and Cosmetic PCL's Debt-to-Equity too high?
Bangkok Lab and Cosmetic PCL's current Debt-to-Equity of 0.23 is 53% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 2.88. The Consumer Packaged Goods industry median Debt-to-Equity is 0.42. Bangkok Lab and Cosmetic PCL's value of 0.23 is 45.2% below this industry median. Based on the distribution chart, Bangkok Lab and Cosmetic PCL ranks #601 out of 1753 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Bangkok Lab and Cosmetic PCL has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bangkok Lab and Cosmetic PCL's Debt-to-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Bangkok Lab and Cosmetic PCL ranks #601 out of 1753 companies for Debt-to-Equity. This puts Bangkok Lab and Cosmetic PCL in the upper half of its industry. The industry median Debt-to-Equity is 0.42. Bangkok Lab and Cosmetic PCL's value of 0.23 is 45.2% below this benchmark. Historically, Bangkok Lab and Cosmetic PCL's own Debt-to-Equity has ranged from 0.07 to 2.88 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.42, Bangkok Lab and Cosmetic PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.42, based on 1,753 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Lab and Cosmetic PCL's current Debt-to-Equity of 0.23 is 45.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bangkok Lab and Cosmetic PCL and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Lab and Cosmetic PCL's current Debt-to-Equity is 0.23, which is 53% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Lab and Cosmetic PCL stock overvalued right now?
Based on GuruFocus' analysis, Bangkok Lab and Cosmetic PCL (BKK:BLC) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿4.75, compared to a current price of ฿3.86 — trading 18.7% below its estimated fair value. The current Debt-to-Equity is 0.23, which is 53% above median its 10-year median of 0.15 and 45.2% below the Consumer Packaged Goods industry median of 0.42. Bangkok Lab and Cosmetic PCL's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bangkok Lab and Cosmetic PCL (BKK:BLC), the current Debt-to-Equity is 0.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bangkok Lab and Cosmetic PCL (BKK:BLC) Overvalued in 2026?
Based on GuruFocus' analysis, Bangkok Lab and Cosmetic PCL stock appears to be undervalued.
The current stock price of ฿3.86 is trading 18.7% below its estimated GF Value™ of ฿4.75.
GuruFocus considers Bangkok Lab and Cosmetic PCL to be Modestly Undervalued.
Key valuation signals for BKK:BLC:
Debt-to-Equity: 0.23 (53% above median its 10-year median of 0.15)
GF Value™: ฿4.75 vs. price of ฿3.86 (18.7% below fair value)
Industry Position: 45.2% below the Consumer Packaged Goods median (#601 of 1753)
No single metric tells the full story. See the BKK:BLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bangkok Lab and Cosmetic PCL are one of Thailand's comprehensive healthcare solutions groups. The principal activities of the Group are the manufacturing and distributing of pharmaceuticals and medicinal chemical products for human and animal It operates in a single line of business, namely pharmaceuticals and medicinal chemical products, The Group derives revenue from sales of goods and rendering of services.
65GF Score
Get the complete analysis for BKK:BLC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BLC has been successfully added to your 
